Dermal Models
GHK-Cu is studied for collagen synthesis; BPC-157 and TB-500 in epithelial and scarring models.
≥99% Purity
Glow
Three-peptide blend · dermal and matrix models
$105.00$52.50/vial with BOGO
USA Lab VerifiedISO/IEC 17025:2017
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
Glow is a blend. Several peptides are combined and freeze-dried into a single 70 mg vial, chosen from compounds studied in skin and connective tissue models. Research on the individual ingredients covers collagen production, tissue structure, and how skin cells move and multiply. It is supplied for researchers testing several pathways together rather than one at a time.
Three-peptide research blend: BPC-157 + TB-500 + GHK-Cu
- Form
- Lyophilized Powder
- Purity
- ≥99% (HPLC verified per component)
- Vial size
- 70mg
- Class
- Peptide blend
0
Synergistic Pathways
VEGF + Actin + Collagen
0×
GHR Upregulation
BPC-157 by day 3
0%
Collagen Synthesis (vs control)
GHK-Cu vs controls
0%
Multi-Phase Coverage
TB-500 re-epithelialization
How It Works
How Glow works
The pathways Glow acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
VEGF Pathway
BPC-157
Vessel formation, tissue granulation and nitric oxide signalling have been measured as endpoints in preclinical models.
- Vessel formation measured
- Tissue granulation scored
- Modulates nitric oxide signaling
Actin Regulation
TB-500
Cell migration, cytoskeletal remodelling and fibrotic scarring are measured via the thymosin beta-4 pathway.
- Cell migration measured
- Cytoskeletal remodelling observed
- Fibrotic scarring scored
Collagen & ECM Remodeling
GHK-Cu
Type I and III collagen synthesis measured, expression changes reported across 4,000+ genes, and copper delivered to tissue during extracellular matrix turnover.
- Type I & III collagen measured
- Modulates 4,000+ genes
- Delivers copper to tissue
Uses & Applications
What Glow is researched for
The main areas Glow is being studied for — and the study-reported figures behind them.
Cytoskeletal & Vascular
TB-500 is characterised for actin remodelling; tendon fibroblast viability is measured for BPC-157; vascularisation endpoints for GHK-Cu.
Anti-Inflammatory
All three peptides demonstrate anti-inflammatory properties through different mechanisms in animal models.
ECM Remodeling
Extracellular matrix deposition and fibrotic scoring as combined endpoints.
Molecular Structure
The Glow molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
Molecular model
Compound Information
Full specification
| Components | BPC-157 + TB-500 + GHK-Cu |
| Strength | 70mg |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified per component) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Light Sensitivity | Protect from direct light at all times |
| Solubility | Water-soluble |
| COA | Included with every order |
| Appearance | White to off-white powder |
| Stability | 24 months from manufacture date when stored properly |
FAQ
Common questions about Glow
GLOW is a research peptide blend containing three peptides: BPC-157 (Body Protection Compound), TB-500 (Thymosin Beta-4), and GHK-Cu (copper peptide). Each is characterised on a different pathway — vascular, cell migration, and collagen synthesis respectively.
In preclinical research, vessel formation (angiogenesis) is measured for BPC-157, cell migration via actin regulation for TB-500, and collagen production plus expression changes across 4,000+ genes for GHK-Cu. The three cover distinct pathways, which is the rationale for combining them.
No. GLOW is not approved by the FDA for any medical use. It is sold exclusively for in vitro laboratory research purposes. The individual components have varying levels of preclinical evidence but no completed human clinical trials for the combined blend.
Store lyophilized (powder) form at -20°C for maximum stability. Protect from direct light at all times and avoid repeated freeze-thaw cycles.
Each component undergoes independent third-party testing including HPLC (High Performance Liquid Chromatography) for purity verification, mass spectrometry for molecular weight confirmation, and endotoxin testing. Certificates of Analysis are included with every order.
The rationale is based on individual component research in preclinical models. The combined blend has not been characterised as a single formulation. Complementarity is inferred from mechanism.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.